Appointment of VP, Scientific & Medical Services
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your DXRX notes
Belfast and London, 5 February - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to pharma and biotech companies, is pleased to announce the appointment of Ken Ruppel as Vice President of Scientific & Medical Services, effective February 1st 2024.
With a commitment to ensuring every patient has access to the right treatment at the right time, Diaceutics welcomes Ken to lead the expansion of current offerings and development of innovative solutions in precision medicine.
Ken joins Diaceutics with an impressive background of over 25 years' experience delivering commercial and operational success in the medical research, life sciences, pharmaceutical, biotechnology and clinical diagnostic markets. He most recently served as VP of Precision Medicine at Amplity Health, where he played a pivotal role in supporting the launch of over 20 companion diagnostic indications across diverse tumour types and laboratory methodologies in the US. His strategic expertise was instrumental in guiding Precision Medicine strategies and tactics for 12 pharmaceutical brands and his impressive track record showcases his dedication to advancing precision medicine initiatives.
In his role at Diaceutics, Ken will lead the identification, development and support of strategic growth opportunities within Scientific & Medical products and services. His responsibilities will include driving innovation and leading client interactions.
Ken's passion and expertise in diagnostic enabled therapies will play a significant role in realising the company's core mission - making precision medicine globally accessible through the DXRX platform.
Susanne Munksted, Chief Precision Medicine Officer at Diaceutics, commented:
"We are extremely pleased to welcome Ken to Diaceutics as our VP Scientific and Medical Services. His proven track record in Precision Medicine aligns seamlessly with our vision, and we are confident in his ability to lead our Scientific and Medical team to be a driving force towards success."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.